To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Sézary's disease
Sézary's disease (or "Sézary syndrome") is a type of cutaneous lymphoma characterized by Albert Sézary.[1] "Sézary's cells" are T-cells that have pathological quantities of mucopolysaccharides. Sézary's disease is sometimes considered a late stage of mycosis fungoides. Product highlight
GeneralSezary syndrome and Mycosis Fungoides are T-cell lymphomas whose primary manifestation is in the skin. EtiologyHTLV has thought to have been associated with both of the above cutaneous mycoses. SymptomsThe hallmark symptoms for Sezary Syndrome are (1) Generalized erythroderma (2)Lymphadenopathy, and (3) Atypical T-cells ("Sezary cells") in the peripheral blood. TreatmentVorinostat (Zolinza®) is a second-line drug for CTCL. Treatments are often used in combination. References
Categories: Hematology | Types of cancer |
|||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sézary's_disease". A list of authors is available in Wikipedia. |
- Johnson & Johnson to Acquire Tibotec- Virco to Expand Portfolio of Treatments For Infectious Diseases and Add to R&D Capability - - Johnson & Johnson expects to incur one-time charge of approximately $145 million in the second quarter
- Novartis pivotal study of Exjade shows significant reduction of iron overload in patients with non-transfusion-dependent thalassemia